Actinogen Medical Reports 30% Slowing of Alzheimer's Progression in Older Patients with Xanamem
Rapid Read

Actinogen Medical Reports 30% Slowing of Alzheimer's Progression in Older Patients with Xanamem

What's Happening? Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has announced a 30% slowing of Alzheimer's disease progression in patients over 75 years old during its XanaMIA clinical trial. This finding, however, did not lead to statistical significance across the entire study population. The company
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.